Dr. Berenson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9201 W Sunset Blvd
Suite 310
West Hollywood, CA 90069Phone+1 310-623-1222Fax+1 310-623-1123- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983
University of Utah HealthResidency, Internal Medicine, 1977 - 1980
University of California San Diego School of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 1980 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Dec 01
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Matthew Brobe...> ;Targeted Oncology. 2024 Apr 20
- Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.Del Dosso, A., Tadevosyan, E., Berenson, J.> ;Oncotarget. 2024 Feb 5
- 1 citationsClinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.Scott Jew, Sean Bujarski, Bernard Regidor, Marsiye Emamy-Sadr, Regina Swift, Benjamin Eades, Susanna Kim, Shahrooz Eshaghian, James R Berenson> ;Targeted Oncology. 2023 Sep 1
- Join now to see all
Abstracts/Posters
- Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple MyelomaJames R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple MyelomaJames R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Po...James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).2019 ASCO Annual Meeting - 6/1/2019
- A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 T...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Other
- Risks of therapy with bone modifying agents in patients with advanced malignancyBerenson JR, Stopeck AT
http://www.uptodate.com/contents/risks-of-therapy-with-bone-modifying-agents-in-patients-with-advanc
UpToDate, Wolters Kluwer Health - 2013-01-22 - The use of bisphosphonates in patients with multiple myelomaBerenson JR
http://www.uptodate.com/contents/the-use-of-bisphosphonates-in-patients-with-multiple-myeloma
UpToDate, Wolters Kluwer Health - 2012-06-29 - Treatment of hypercalcemiaBerenson JR, Shane E
http://www.uptodate.com/contents/treatment-of-hypercalcemia
UpToDate, Wolters Kluwer Health - 2012-09-12
Press Mentions
Ruxolitinib and Methylprednisolone for Treatment of Patients with relapsed/refractory Multiple MyelomaDecember 20th, 2022- Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual MeetingDecember 8th, 2022
- How Immunocompromised People Without Strong Vaccine Protection Are Coping with COVIDNovember 9th, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
